venous-thromboembolism

Documents about venous-thromboembolism

• Mortality Due to Malignancy in Patients With Idiopathic Venous Thromboembolism#833126ClinicalTrials.gov
• Thrombosis Outcomes in Pediatric Venous Thromboembolism#363516ClinicalTrials.gov
• The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma#873224ClinicalTrials.gov
• COVID-19 and Venous Thromboembolism Risk#969300ClinicalTrials.gov
• Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism#889384ClinicalTrials.gov
• Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial#882852ClinicalTrials.gov
• Risk Factors and Outcomes of Acute Venous Thromboembolism in Cirrhotic#981705ClinicalTrials.gov
• Venous Thromboembolism Taskforce Audit Program#914574ClinicalTrials.gov
• Apixaban for the Acute Treatment of Venous Thromboembolism in Children#836766ClinicalTrials.gov
• Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection#850881ClinicalTrials.gov
• Smart Technology Facilitated Patient-centered Venous Thromboembolism Management#249708ClinicalTrials.gov
• Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer#871988ClinicalTrials.gov
• Incidence of Venous Thromboembolism and Professional Practices in Brest Area#889509ClinicalTrials.gov
• Venous Thromboembolism in Pregnant and Puerperal Women in Denmark 1995-2005#891226ClinicalTrials.gov
• Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients#981015ClinicalTrials.gov
• Predicting the Risk of Venous Thromboembolism in Critically Ill Patients#1008624ClinicalTrials.gov
• Prospective Validation of Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery#800457ClinicalTrials.gov
• EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization#855307ClinicalTrials.gov
• Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients#875787ClinicalTrials.gov
• Venous Thromboembolism in DM1#912800ClinicalTrials.gov
• Impact of Early Debriefing and Enhanced Educative Components on Direct Oral Anticoagulant Adherence After Venous Thromboembolism.#882039ClinicalTrials.gov
• Can Thrombin Generation Measurement Predict the Risk of Venous Thromboembolism in Acute Ill Patients#855255ClinicalTrials.gov
• Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients#882610ClinicalTrials.gov
• Clonal Hematopoiesis of Indeterminate Potential in Venous Thromboembolism#905726ClinicalTrials.gov
• Aspirin for the Prevention of Recurrent Venous Thromboembolism#902895ClinicalTrials.gov
• Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism#11543HAL (France)
• The China Pulmonary Thromboembolism Registry Study#811346ClinicalTrials.gov
• Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)#837764ClinicalTrials.gov
• Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)#853534ClinicalTrials.gov
• Incidence and Outcomes of Venous Thromboembolism#873146ClinicalTrials.gov
• Long-term Surveillance of Patients With Venous Thromboembolism: a Nationwide Prospective Cohort Study#882095ClinicalTrials.gov
• Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial#1008921ClinicalTrials.gov
• EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin#801672ClinicalTrials.gov
• Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients#813702ClinicalTrials.gov
• EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol#886497ClinicalTrials.gov
• Risk of Pulmonary and Venous Thromboembolism in Pregnancies After in Vitro Fertilization#889749ClinicalTrials.gov
• Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism#898014ClinicalTrials.gov
• Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy#905536ClinicalTrials.gov
• Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study#1000752HAL (France)
• Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery#877537ClinicalTrials.gov
• Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients#886331ClinicalTrials.gov
• A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients#901563ClinicalTrials.gov
• Epidemiology of Venous Thromboembolism#834987ClinicalTrials.gov
• Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey#315180IRIS
• Anti Xa Monitoring Low Molecular Weight Heparin on Prevention of Venous Thromboembolism#875706ClinicalTrials.gov
• Follow-up in Rivaroxaban Patients in Setting of Thromboembolism#121516ClinicalTrials.gov
• Mexican Multidisciplinary Registry of Patients With Venous Thromboembolic Disease#861788ClinicalTrials.gov
• Management of Recurrent Venous Thromboembolism During Anticoagulant Treatment in Cancer Patients - a Prospective Cohort Study#141147ClinicalTrials.gov
• Smart Technology Facilitated Venous Thromboembolism Prophylaxis Based on Bundled Evidence-based Prevention Strategies#836734ClinicalTrials.gov
• WHITE Study: WHIch Decision After a First Venous ThromboEmbolism?#910414ClinicalTrials.gov